Table 2.
Correlation of Notch3 or GATA-3 expression with clinicopathological status in 72 patients with breast cancer
| Clinicopathologic features | Notch3-(n = 29) | Notch3+ (n = 43) | P | GATA-3- (n = 19) | GATA-3+ (n = 53) | P |
|---|---|---|---|---|---|---|
| Age at diagnosis | 0.598 | 0.603 | ||||
| <50 | 13(44.8%) | 22(51.2%) | 8(42.1%) | 26(49.1%) | ||
| ≥50 | 16(55.1%) | 21(48.8%) | 11(57.9%) | 27(50.9%) | ||
| Menstrual conditions | 0.35 | 0.303 | ||||
| premenopausal | 15(51.7%) | 27(62.8%) | 9(47.4%) | 29(54.7%) | ||
| postmenopausal | 14(48.3%) | 16(37.2%) | 10(52.6%) | 24(45.3%) | ||
| Tumor size (cm) | 0.095 | 0.109 | ||||
| <2 | 12(41.3%) | 8(18.6%) | 7(36.8%) | 13(24.5%) | ||
| ≥2, <5 | 11(37.9%) | 25(58.1%) | 11(57.9%) | 25(47.2%) | ||
| ≥5 | 6(20.7%) | 10(23.3%) | 1(5.7%) | 15(28.3%) | ||
| LN metastasis | 0.026* | 0.021* | ||||
| 0 | 13(44.8%) | 29(67.4%) | 9(47.4%) | 33(62.3%) | ||
| 1–3 | 2(6.9%) | 6(14.0%) | 1(5.7%) | 11(20.8%) | ||
| ≥4 | 14(48.3%) | 8(18.6%) | 9(47.4%) | 9(17.0%) | ||
| Histological grade | 0.287 | 0.963 | ||||
| I | 3(10.3%) | 9(20.9%) | 3(15.8%) | 9(17.0%) | ||
| II | 15(51.7%) | 24(55.8%) | 10(52.6%) | 29(54.7%) | ||
| III | 11(37.9%) | 10(23.6%) | 6(31.6%) | 15(28.3%) | ||
| Stage | 0.411 | 0.111 | ||||
| I–II | 17(58.6%) | 29(67.4%) | 15(78.9%) | 31(58.5%) | ||
| III–IV | 12(41.3%) | 14(32.6%) | 4(21.1%) | 22(41.5%) | ||
| ER | 0.027* | 0.038* | ||||
| Positive | 15(51.7%) | 33(76.7%) | 9(47.4%) | 39(73.6%) | ||
| Negative | 14(48.3%) | 10(23.6%) | 10(52.6%) | 14(26.4%) | ||
| PR | 0.048* | 0.027* | ||||
| Positive | 13(44.8%) | 29(67.4%) | 7(36.8%) | 35(66.0%) | ||
| Negative | 16(55.2%) | 14(32.6%) | 12(63.2%) | 18(34.0%) | ||
| HER-2 | 0.552 | 0.64 | ||||
| Positive | 10(34.5%) | 12(27.9%) | 5(26.3%) | 17(32.1%) | ||
| Negative | 19(65.5%) | 31(72.1%) | 14(73.7%) | 36(67.9%) | ||
| Ki67 status | 0.814 | 0.128 | ||||
| <14% | 17(58.6%) | 24(55.8%) | 8(42.1%) | 33(62.3%) | ||
| ≥14% | 12(41.4%) | 19 (44.2%) | 11(57.9%) | 20(37.7%) | ||
| Breast cancer subtypes | 0.169 | 0.28 | ||||
| Luminal A | 9(31.0%) | 25(58.1%) | 7(36.8%) | 27(50.9%) | ||
| Luminal B/HER-2 Neg | 4(13.8%) | 4(9.3%) | 1 (5.7%) | 7(13.2%) | ||
| Luminal B/HER-2 Pos | 2(6.9%) | 4(9.3%) | 1 (5.7%) | 5(9.4%) | ||
| HER-2 | 5(17.2%) | 4(9.3%) | 3(15.8%) | 6(11.3%) | ||
| TNBC | 9(31.0%) | 6(14.0%) | 7(36.8%) | 8(15.1%) |
LN lymph node, ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor-2
*P-value < 0.05 was considered statistically significant